Precisedx Raises $10.75 Million Series A Preferred From Healthcare Industry Leaders To Commercialize Cancer Risk Stratification Services To Support Better Patient Insights And Outcomes
Precisedx Raises $10.75 Million Series A Preferred From Healthcare Industry Leaders To Commercialize Cancer Risk Stratification Services To Support Better Patient Insights And Outcomes
01/11/22, 8:30 AM
Money raised
$10.8 million
Round Type
series a
PreciseDx, the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, announced that it has raised $10.75 million in Series A Preferred in 2021 funding to support the ongoing development and commercialization of its AI-powered risk stratification platform. Leveraging AI insights and data derived from high-volume, well-annotated study populations, PreciseDx offers breast cancer diagnostic test services, with a prostate cancer test in development. The use of morphology features to stratify cancer risk provides valuable insights into cancer treatment, attracting the attention of healthcare innovators. The Company also announced the appointment of industry veteran Wayne Brinster to Chief Executive Officer, which was effective September 2021
Company Info
Additional Info
PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient. Combining the power of artificial intelligence with its proprietary Morphology Feature ArrayTM, PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making. For more information, visit www.precisedx.ai